OP0595, a new diazabicyclooctane: mode of action as a serine beta-lactamase inhibitor, antibiotic and beta-lactam 'enhancer'
Morinaka, A., Tsutsumi, Y., Yamada, M., Suzuki, K., Watanabe, T., Abe, T., Furuuchi, T., Inamura, S., Sakamaki, Y., Mitsuhashi, N., Ida, T., Livermore, D.M.(2015) J Antimicrob Chemother 70: 2779-2786
- PubMed: 26089439 
- DOI: https://doi.org/10.1093/jac/dkv166
- Primary Citation of Related Structures:  
4X68, 4X69 - PubMed Abstract: 
The production of a growing diversity of β-lactamases by Gram-negative bacteria challenges antimicrobial chemotherapy. OP0595, discovered separately by each of Meiji Seika Pharma and Fedora Pharmaceuticals, is a new diazabicyclooctane serine β-lactamase inhibitor that also acts as an antibiotic and as a β-lactamase-independent β-lactam 'enhancer'.
Organizational Affiliation: 
Meiji Seika Pharma Co., Ltd, Yokohama, Japan akihiro.morinaka@meiji.com.